Back to top
more

Charles River Laboratories International, Inc. (CRL)

(Delayed Data from NYSE)

$342.55 USD

342.55
320,022

+5.71 (1.70%)

Updated May 7, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (199 out of 254)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.

General Information

Charles River Laboratories International, Inc.

251 BALLARDVALE STREET

WILMINGTON, MA 01887

Phone: 781-222-6000

Fax: 978-988-5665

Web: http://www.criver.com

Email: askcharlesriver@crl.com

Industry Medical Services
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 8/4/2021

EPS Information

Current Quarter EPS Consensus Estimate 2.26
Current Year EPS Consensus Estimate 9.61
Estimated Long-Term EPS Growth Rate 14.00
Next EPS Report Date 8/4/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 336.84
52 Week High 349.13
52 Week Low 157.11
Beta 1.14
20 Day Moving Average 340,301.06
Target Price Consensus 328.70

CRL

% Price Change
4 Week 12.24
12 Week 18.43
YTD 37.10
% Price Change Relative to S&P 500
4 Week 8.65
12 Week 9.58
YTD 20.52
Share Information
Shares Outstanding (millions) 50.25
Market Capitalization (millions) 17,214.16
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 35.63
Trailing 12 Months 38.79
PEG Ratio 2.54
EPS Growth
vs. Previous Year 37.50%
vs. Previous Quarter 5.86%
   
Sales Growth
vs. Previous Year 16.62%
vs. Previous Quarter 4.24%
   
Price Ratios
Price/Book 7.87
Price/Cash Flow 26.38
Price / Sales 5.66
ROE
3/31/21 22.54
12/31/20 22.15
9/30/20 22.41
ROA
3/31/21 8.25
12/31/20 7.78
9/30/20 7.66
Current Ratio
3/31/21 1.77
12/31/20 1.43
9/30/20 1.45
Quick Ratio
3/31/21 NA
12/31/20 1.21
9/30/20 1.22
Operating Margin
3/31/21 14.76
12/31/20 14.07
9/30/20 13.79
Net Margin
3/31/21 12.33
12/31/20 12.46
9/30/20 10.68
Pre-Tax Margin
3/31/21 15.06
12/31/20 15.29
9/30/20 13.47
Book Value
3/31/21 43.54
12/31/20 42.55
9/30/20 38.23
Inventory Turnover
3/31/21 10.49
12/31/20 10.60
9/30/20 10.62
Debt-to-Equity
3/31/21 1.01
12/31/20 0.91
9/30/20 1.04
Debt to Capital
3/31/21 50.48
12/31/20 48.00
9/30/20 51.17